Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
Dermatology and Therapy, August 8, 2023
In collaboration with industry and academic researchers, Analysis Group consultants have coauthored a study implementing their novel method for assessing the long-term effectiveness of pharmaceutical treatments. In the study, the authors applied this method, which tracks individual patient responses to periodic surveys over time about their experiences following the use of dupilumab to treat atopic dermatitis (AD).
The method – Longitudinal Surveys of Patients with Recruitment Through Patient Support Programs (LEAP) – was used to collect real-world data (RWD) on patient-reported outcomes (PROs) about topics such as status in symptoms and changes in quality of life and productivity. In doing so, researchers extended previously reported results to include RWD from patients 30–36 months after initiation of treatment. This allowed the team to assess the long-term effectiveness of dupilumab as an AD treatment.
Analysis Group Managing Principal Eric Q. Wu, Vice President Min Yang, and Manager Bruno Martins collaborated with researchers from Harvard Medical School, the Yale School of Medicine, Sanofi, and Regeneron Pharmaceuticals. The study, “Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study,” was published in Dermatology and Therapy.
Read about a related 2021 study
Authors
Kimball AB, Delevry D, Yang M, Chuang C, Wang Z, Bégo-Le-Bagousse G, Martins B, Wu EQ, Shumel B, Wang J, Sierka D, Chao J, Strober B